TAIPEI, Oct. 1, 2025 /PRNewswire/ — TAHO Pharmaceuticals Ltd. (“TAHO Pharma”) today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for TAH3311, the world’s first Apixaban […]
Tag: Taho Pharmaceuticals
TAHO Pharmaceuticals meldet positive Ergebnisse der Pivotalstudie zu TAH3311, dem ersten oralen Antikoagulans in Filmform
TAIPEI, 17. Februar 2025 /PRNewswire/ — TAHO Pharmaceuticals gibt positive vorläufige Ergebnisse der Zulassungsstudie von TAH3311, dem weltweit ersten oral auflösenden Film (ODF) von Apixaban, bekannt. Die Studie bestätigte, dass TAH3311 unter Nüchternbedingungen bioäquivalent zu […]
TAHO Pharmaceuticals Initiates U.S. Phase III Clinical Trial of TAH3311 Antithrombotic Oral Dissolving Film, Dosing First Subjects
TAIPEI, Nov. 19, 2024 /PRNewswire/ — TAHO Pharmaceuticals Ltd. announced the dosing of the first subjects in its U.S. Phase III clinical trial for its lead product, TAH3311, an innovative antithrombotic oral dissolving film (ODF). […]
